Tinuviel Therapeutics is proud to contribute to Wellcome Leap's Foundations of a Resilient Microbiome (FORM) program, a global program bringing together leading researchers, clinicians, engineers and technology innovators to accelerate breakthroughs in our understanding of microbiome resilience in early life and its role in human neurodevelopment. Through FORM, Tinuviel is developing a first-of-its-kind human microbiome digital twin platform that enables the measurement, prediction, and engineering of microbiome resilience in early life, with the potential to power next-generation screening, diagnostics and precision microbiome therapeutics to build developmental resilience early in life.

Tinuviel Therapeutics and Hudson Institute of Medical Research are partnering through Wellcome Leap’s FORM program to bridge world-class experimental microbiome science with advanced computational biology. By combining Hudson’s expertise in microbial culturing, systems biology, and translational microbiome research with Tinuviel’s capabilities in artificial intelligence and digital-twin modeling, the collaboration is creating a closed-loop experimental-computational platform to measure, model, and predict human microbiome resilience, opening new pathways for precision diagnostics, predictive medicine, and therapeutic design.

Tinuviel Therapeutics and JIJ are partnering through Wellcome Leap’s FORM program to develop next-generation computational frameworks for modeling microbiome dynamics and resilience. By combining JIJ’s expertise in mathematical optimization and advanced computing with Tinuviel’s capabilities in systems biology and digital-twin modeling, the collaboration is advancing microbiome analysis beyond description toward prediction, resilience modeling, and precision intervention design.

Tinuviel Therapeutics and Kipu Quantum are partnering through the NEDO program to apply quantum and hybrid quantum-classical solutions with quantum-enhancement to one of medicine’s most urgent challenges: multidrug-resistant infections. By combining Kipu Quantum’s advanced algorithms with Tinuviel’s expertise in microbiome science and precision therapeutic design, the collaboration aims to model complex microbial ecosystems, identify optimal intervention strategies, and accelerate the development of next-generation therapeutics against drug-resistant pathogens.